Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002556 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 312
- Enrollment target
NCT00002556: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00002556 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 312 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002556, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 312 participants
- Enrollment target
Study Summary
This randomized phase III clinical trial studies combination chemotherapy with high dose cyclophosphamide and recombinant interferon alfa-2b to see how well it works compared to combination chemotherapy alone in treating patients with previously untreated stage I-III multiple myeloma. Drugs used in chemotherapy, such as vincristine sulfate, carmustine, melphalan, cyclophosphamide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of cancer cells. It is not yet know whether giving combination chemotherapy with or without alternating high-dose cyclophosphamide and recombinant interferon alfa-2b is more effective in treating multiple myeloma.
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG melphalan
- DRUG carmustine
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 1994-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002556
The ClinicalTrials.gov registry entry for NCT00002556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00002556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002556 about?
NCT00002556 is a clinical study titled "Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma". This randomized phase III clinical trial studies combination chemotherapy with high dose cyclophosphamide and recombinant interferon alfa-2b to see how well it works compared to combination chemotherapy alone in treating patients with previously untreated stage I-III multiple myeloma. Drugs used in ...
What is the current status of trial NCT00002556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 1994-07.
What interventions are being tested in trial NCT00002556?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), melphalan (DRUG), carmustine (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00002556?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.